Philip Kern
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Philip Kern sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Philip Kern: 9 sponsored US clinical trials, 2 recruiting.
Philip Kern sponsors 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is PreDiabetes, with 2 trials.
Top-decile sponsor footprint
Philip Kern ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
NCT05051436
Mechanisms for Activation of Beige Adipose Tissue in Humans
NCT04666636
RELIANCE: Moringa in Lactation and Early Childhood
NCT07605091
Brown Fat Activation Study
NCT02919176
Cold Induced Changes in White Adipose
NCT02596776
Blood Lipopolysaccharide (LPS) Rifaximin Study
NCT02124512
Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)
NCT02308228
Effects of Fish Oils on Inflammation and Insulin Resistance
NCT00579436
Mechanisms Underlying Metabolic Syndrome in Obesity
NCT00579813
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Philip Kern pipeline
2 recruiting of 9 indexed (22% open); 6 completed (67%).
Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: PreDiabetes (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Philip Kern: open-pipeline peers nationwide
Peers matched on 9 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Philip Kern sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 22% open enrollment (± trial volume)
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
- Englewood Hospital and Medical Center · 22% recruiting · 18 trials
- Ensysce Biosciences · 22% recruiting · 9 trials
Related
What to do with this Philip Kern page
9 registered trials is a research-attention snapshot, not an endorsement of Philip Kern or any single study.
- 2 of Philip Kern's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- PreDiabetes is the condition Philip Kern studies most, compare against other sponsors active in the same condition before evaluating a specific study. See PreDiabetes trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Philip Kern pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.